Journal of Ovarian Research最新文献

{"title":"Predictive value of preoperative systemic immune-inflammation index and prognostic nutrition index in patients with epithelial ovarian cancer.","authors":"Jingping Chen, Lu Jin, Rui Luo, Xiaofei Zhang, Yizhi Chen, Ze Han, Tianfeng Liu","doi":"10.1186/s13048-025-01631-4","DOIUrl":"10.1186/s13048-025-01631-4","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the predictive value of Prognostic Nutritional Index (PNI), Systemic Immunoinflammatory Index (SII), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) in patients with epithelial ovarian cancer ( EOC). Also, to explore the predictive value of a new scoring system combining PNI and SII (coPNI-SII) in patients with EOC.</p><p><strong>Methods: </strong>In this study, 154 patients with EOC were analyzed and classified according to the best cut-off values for SII, PNI, PLR, and NLR. Spearman's rank correlation was used to analyze the correlation of variables. The Kaplan-Meier survival curve and log-rank test were used to investigate the relationship between inflammatory indicators and overall survival (OS), which was then followed by a multivariate Cox proportional hazards model. All patients were categorized into three groups based on PNI-SII scores. The coPNI-SII score ranged from 1 to 3 as follows: score of 1, high PNI (≥ 48.98) and low SII(< 998.87); score of 2, high PNI and high SII or low PNI and low SII; score of 3, low PNI and high SII. To assess the prognostic value of coPNI-SII in patients with EOC.</p><p><strong>Results: </strong>The areas under the ROC curves for SII, PNI, PLR, NLR, and coPNI-SII were 0.814, 0.814, 0.780, 0.769, and 0.860, respectively. The optimal cut-off values for SII, PNI, PLR, and NLR were 998.87, 48.98, 217.63, and 2.61, respectively. The Kaplan-Meier analysis showed that the OS of the patients in the high PNI group, low SII group, low NLR group, and low PLR group was significantly higher than that of the patients in the low PNI group, high SII group,high NLR group, and high PLR group (p < 0.01). SII (P = 0.034), PNI (P = 0.013), FIGO staging (P = 0.009), ascites (P = 0.003), CA199 (P = 0.003), HE4 (P = 0.028), residual lesions (P = 0.022), and margins of incision (P < 0.001) were found to be significant prognostic indicators of OS by multifactorial Cox regression analysis. There was a significant inverse relationship between the PNI and SII (r = -0.484; P < 0.01). EOC patients with a coPNI-SII score of 1 had a higher 5-year OS rate (P < 0.05) than EOC patients with a coPNI-SII score of 2 or 3. When taking into account both the SII and PNI, the predictive value rose.</p><p><strong>Conclusion: </strong>Interestingly, we found that low preoperative PNI and high SII were strong indicators of poor prognosis in patients with EOC. The combination of SII and PNI can enhance the accuracy of prognosis.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"45"},"PeriodicalIF":3.8,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11887369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Nigella sativa-L supplementation on glycemia in adolescent polycystic ovarian syndrome: secondary analysis of a randomized controlled trial study.","authors":"Azamsadat Mahmoudian, Akram Ashouri, Fatemeh Mohammadzadeh, Roghaieh Rahmani Bilandi, Sareh Dashti, Narjes Bahri","doi":"10.1186/s13048-025-01634-1","DOIUrl":"10.1186/s13048-025-01634-1","url":null,"abstract":"<p><strong>Introduction: </strong>Adolescence is a critical period for health, as conditions like polycystic ovarian syndrome (PCOS) can affect long-term outcomes, including diabetes and other non-communicable diseases in adulthood. This study evaluated the effects of Nigella sativa L. extract on glycemia among adolescents with PCOS.</p><p><strong>Materials and methods: </strong>This secondary analysis used data from a randomized controlled trial conducted between March 2022 and March 2023. One hundred sixteen adolescent girls aged 12-18 years with PCOS were randomized into two groups. The intervention group received 1000 mg/day of Nigella sativa extract for 16 weeks, while the control group received 10 mg/day of medroxyprogesterone for 10 days per menstrual cycle over the same period. Fasting plasma glucose (FPG) and one- and two-hour post-prandial glucose levels were measured at baseline and after the intervention.</p><p><strong>Results: </strong>103 completed the study (50 in the Nigella sativa group and 53 in the control group). At baseline, there were no significant differences in FPG (p = 0.294), though the control group had higher one-hour (p = 0.002) and two-hour (p = 0.006) post-prandial glucose levels. Post-intervention, significant interaction effects were observed for FPG (p = 0.004) and two-hour post-prandial glucose (p = 0.023), indicating more significant reductions in the Nigella sativa group compared to the control group.</p><p><strong>Conclusions: </strong>Considering the observed effect of Nigella sativa supplementation on FPG and two-hour post-prandial glucose, it may offer a complementary approach to managing glycemia in adolescent PCOS. However, further research is warranted.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"46"},"PeriodicalIF":3.8,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11887340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case report.","authors":"Yong Wu, Lingfang Xia, Chunyan Song, Xiaojun Chen, Xiaohua Wu","doi":"10.1186/s13048-025-01628-z","DOIUrl":"10.1186/s13048-025-01628-z","url":null,"abstract":"<p><p>Ovarian cancer, colloquially termed the \"king of gynecological cancers,\" presents significant diagnostic and therapeutic challenges due to its covert nature. It ranks as the deadliest gynecologic malignancy with a disheartening 5-year survival rate below 40%. Standard therapeutic protocols for newly diagnosed patients encompass cytoreductive surgery followed by neoadjuvant or adjuvant platinum-based chemotherapy. Despite initial chemotherapeutic responses, recurrence is common, affecting up to 80% of patients, with nearly all developing eventual resistance to chemotherapy regimens. This case report highlights an Aisan patient with ovarian cancer, who exhibited tolerance, recurrence, and progression after several prior lines of treatment. The application of Mirvetuximab Soravtansine, facilitated by positive FRα expression identified through IHC analysis, notably reduced tumor lesions and CA125 levels, achieving a complete response and maintaining low CA125 levels during treatment, underscoring its efficacy in treating platinum-resistant recurrent ovarian cancer.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"43"},"PeriodicalIF":3.8,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11887124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ameliorative effect of Fagonia indica-coated chitosan nanoparticles on the ovulatory pattern in PCOS rat model.","authors":"Threem Zia, Irfana Liaqat, Khawar Ali Shahzad, Mushtaq Hussain Lashari, Dalia Fouad, Farid S Ataya, Saman Alam, Areeba Saeed","doi":"10.1186/s13048-025-01635-0","DOIUrl":"10.1186/s13048-025-01635-0","url":null,"abstract":"<p><strong>Background: </strong>Polycystic ovarian syndrome (PCOS) with wide-range prevalence, affecting 5-18% of females of reproductive age, and its substantive role as a primary etiological factor in anovulatory infertility, with up to 80% of such cases attributed to this syndrome having particular significance.</p><p><strong>Objectives: </strong>The current research delineates the outcomes of a meticulous inquiry into the efficacy of Fagonia indica-coated chitosan nanoparticles (FICNPs) in ameliorating the prevalent and clinically consequential PCOS in female Wistar rats.</p><p><strong>Methodology: </strong>FICNPs were synthesized by using a methanolic extract of F. indica and chitosan via the ion gelatin method. The nuanced interplay of hormonal profiles, ovarian histology, and miRNA expression in response to FICNPs intervention was investigated. Notable findings include an obvious decrease in luteinizing (LH) and testosterone hormone levels with high-dose FICNPs-treated subjects (100 mg/kg) compared to their untreated counterparts.</p><p><strong>Results: </strong>Follicle-stimulating hormone (FSH) and prolactin levels were markedly decreased in the untreated PCOS rat models, whereas, histopathological examination revealed augmented oocyte diameters in FICNP-treated rats, suggesting pronounced improvements in ovarian morphogenesis and follicular maturation. Additionally, real-time quantitative PCR analysis revealed disparate miRNA expression profiles, prominently implicating rno-miR-30c-2-3p, rno-miR-146b-5p, rno-miR-486, and rno-miR-3586-3p in the therapeutic efficacy of FICNPs. Notably, the progeny of FICNPs-treated subjects (F1 generation) showed normalized ovulatory activity, substantiating the sustained therapeutic potential of FICNPs.</p><p><strong>Conclusion: </strong>Collectively, these findings underscore the auspicious promise of FICNPs as a paradigm-shifting therapeutic modality for mitigating the complex pathophysiology of PCOS, thereby addressing its formidable prevalence and clinical import, with the potential to surpass conventional pharmacotherapy modalities.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"44"},"PeriodicalIF":3.8,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11887359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SRC involves in lysosomal function and regulates ferroptosis in polycystic ovary syndrome.","authors":"Tianmei Wang, Xin Chen, Cong Li","doi":"10.1186/s13048-025-01637-y","DOIUrl":"10.1186/s13048-025-01637-y","url":null,"abstract":"<p><strong>Background: </strong>The pathogenesis of polycystic ovary syndrome (PCOS) is still unknown, so finding the molecular mechanisms of pathogenesis is crucial in PCOS.</p><p><strong>Methods: </strong>The GSE34526 dataset from the Gene Expression Omnibus (GEO) database was used to screen biomarkers in this study. KEGG enrichment analysis of GSE34526 was performed using Gene Set Enrichment Analysis (GSEA). The differentially expressed genes(DEGs) were screened and analyzed for lysosome-related genes. Subsequently, further KEGG and GO analyses were performed, and it was found that it was enriched in the ferroptosis pathway, and then the ferroptosis-related differential genes were obtained. The genes at the core position were obtained by the Protein-Protein Interaction(PPI) network. We then focused our attention on SRC and verified the differential expression of SRC in ovarian tissues of hyperandrogenemic, hyperlipemic and control groups, as well as the differences in conception rate and litter rate of each group by rat test.</p><p><strong>Results: </strong>GSEA analysis of the gene dataset GSE34526 revealed that LYSOSOME was significantly enriched in the PCOS group. There were 188 lysosome-related differentially expressed genes(LRDEGs) in granulosa cells from patients with PCOS, and 41 ferroptosis-related differentially expressed genes(FRDEGs). It was found that six of these genes, SRC, NCF2, SLC2A8, FTL, SLC2A6, SLC3A2, were present in all three datasets. SRC was the top ranked gene in the PPI network of FRDEGs.As verified by the rat model, the expression of SRC in the ovarian tissues of the hyperandrogenemic group was significantly higher than that of the control group (P=0.004) and the hyperlipemic group (P=0.002).</p><p><strong>Conclusion: </strong>SRC, as an important gene involved in lysosomal function and regulating ferroptosis, is expected to be a potential target for PCOS.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"42"},"PeriodicalIF":3.8,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of systemic immune inflammation index for ovarian cancer: An updated systematic review and meta-analysis.","authors":"Boliang Chu, Yingying Chen, Jiewei Pan","doi":"10.1186/s13048-025-01626-1","DOIUrl":"10.1186/s13048-025-01626-1","url":null,"abstract":"<p><strong>Objective: </strong>Several inflammatory indices have been used to assess the prognosis of ovarian cancer, with variable results. This review assessed whether the systemic immune inflammation index (SII) can predict outcomes in patients with ovarian cancer.</p><p><strong>Methods: </strong>Embase, PubMed, CENTRAL, Web of Science, and Scopus databases were searched by the two reviewers from inception to 15th October 2024 for studies assessing the relationship between SII and overall survival (OS) or disease-free survival (DFS).</p><p><strong>Results: </strong>Ten studies with eleven cohorts were included. Pooled analysis showed that higher SII was a significant predictor of poor OS (HR: 2.35 95% CI: 1.56, 3.55 I² = 88%) and worse DFS (HR: 2.51 95% CI: 1.71, 3.67 I² = 80%) after ovarian cancer. Sensitivity analysis failed to change the significance of the results. No publication bias was noted. Most results remained significant on subgroup analyses based on location, sample size, FIGO stage, treatment, adjusted outcomes, cut-off of SII, method of determining cut-off, and quality score.</p><p><strong>Conclusions: </strong>SII can be a potential predictor of OS and DFS after ovarian cancer. Further studies are required to improve the evidence.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"41"},"PeriodicalIF":3.8,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of age at menarche and different causes of infertility: a retrospective study of 7634 women undergoing assisted reproductive technology.","authors":"Miaomiao Ban, Jiejing Jiao, Jiayi Zhou, Linlin Cui, Huidan Wang, Zi-Jiang Chen","doi":"10.1186/s13048-025-01629-y","DOIUrl":"10.1186/s13048-025-01629-y","url":null,"abstract":"<p><strong>Background: </strong>Infertility has become a world-wide public health problem. To identify women in a high-risk of infertility at an early stage when more treatments are available, early risk factors such as age at menarche (AAM) are being investigated. AAM is often used in epidemiological studies as a marker of the timing of pubertal development and the onset of the hypothalamic-pituitary-ovarian axis functions. Therefore, our study aimed to elucidate the association of AAM and different infertility causes in women undergoing assisted reproductive technology.</p><p><strong>Methods: </strong>A total of 7643 women were retrospectively included from the reproductive hospital affiliated with Shandong University between January 2017 and December 2019. Multivariate logistic regression models and restricted cubic spline (RSC) were performed to analyze the relationship between AAM and different infertility causes. Information on variables was obtained from medical records.</p><p><strong>Results: </strong>Compared with primary infertility, secondary infertility would 7.7% increase risk with each one-year increase in menarche age after adjusted odds ratio (OR) [95% confidence interval (CI)], 1.077 (1.036, 1.119). In primary infertility group, each one-year increase in menarche age corresponded with a 16.7% increase in PCOS risk OR (95% CI), 1.218 (1.138, 1.303). AAM of women with DOR were significantly decreased in primary and secondary infertility group [OR (95% CI), 0.832 (0.716, 0.965) and OR (95% CI), 0.720 (0.603, 0.859)], respectively compared with the reference group. Moreover, there is a non-linear dose-response relationship between DOR (P < 0.001) with AAM.</p><p><strong>Conclusion: </strong>This study demonstrates a significant impact of AAM on endocrine-related infertility in women. Further research on the relationship between the onset of menarche and the pathogenesis of infertility is warranted.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"40"},"PeriodicalIF":3.8,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring new frontiers in oncofertility preservation: a case of ovarian stimulation during pregnancy.","authors":"Parisa Pirooznia, Esmat Mashhadi Meighani, Firouzeh Ghaffari","doi":"10.1186/s13048-025-01615-4","DOIUrl":"10.1186/s13048-025-01615-4","url":null,"abstract":"<p><strong>Background: </strong>The standard treatment for Pregnancy-Associated Breast Cancer (PABC) includes surgery and neoadjuvant chemotherapy, which can impair fertility, emphasizing the critical need for fertility preservation in these patients. This case report discusses a breast cancer patient who was found to be pregnant shortly after starting treatment. Despite the pregnancy and increased levels of βHCG and progesterone, the ovarian stimulation cycle yielded a satisfactory number of mature oocytes and high-quality embryos.</p><p><strong>Case presentation: </strong>A 40-year-old woman, G1Ab1 (Gravida1Abortion1), who was diagnosed with Invasive Ductal Carcinoma with negative receptors (Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2) was referred to the oncofertility unit of the Royan Infertility Center for fertility preservation prior to the commencement of chemotherapy. Following necessary consultations and procedures, and confirming a negative pregnancy test, a random start letrozole-based protocol was initiated for ovarian stimulation. During the cycle, a positive pregnancy test was encountered. Despite the positive test, the cycle continued, and on day 13 of the cycle, triggering was performed with a GnRH agonist. A puncture was performed 36 h later, yielding 12 oocytes and 8 embryos.</p><p><strong>Conclusion: </strong>This case highlights the feasibility of adapting random-start ovarian stimulation protocols during pregnancy, warranting further investigation in similar clinical scenarios.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"39"},"PeriodicalIF":3.8,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interference with CHD1L inhibits the malignant progression and enhances cisplatin sensitivity of ovarian cancer cells by binding PLK1.","authors":"Kun Qiao, Yuanxiazi Guan, Wenjing Xing","doi":"10.1186/s13048-024-01582-2","DOIUrl":"10.1186/s13048-024-01582-2","url":null,"abstract":"<p><strong>Background: </strong>Chromodomain helicase/ATPase DNA-binding protein 1-like gene (CHDIL) is an oncogene with abnormal expression in ovarian cancer (OC), but its regulatory role in the malignant biological properties of OC cells and its mechanisms have not been reported.</p><p><strong>Methods: </strong>In this study, CHD1L and polo-like Kinase 1 (PLK1) expression in OC tissues and OC cell lines was analyzed. After CHD1L silencing, CAOV-3 cell proliferation and apoptosis were detected by CCK8 assay, EDU and TUNEL staining. Flow cytometry was used to detect cell cycle. CCK8 assay and TUNEL were used to detect the role of CHD1L in the sensitivity of OC cells to cisplatin. In addition, the abilities of CAOV-3 cell migration and invasion were evaluated using wound healing assay and transwell assay. Next, the binding between CHD1L and PLK1 was investigated using co-immunoprecipitation assay. Then, PLK1 was overexpressed to perform the rescue experiments to analyze the regulation mechanism of CHD1L on OC development and cisplatin sensitivity. Moreover, the transplantation tumor model of CAOV-3 cells in nude mice was established to explore the antineoplastic effect of CHD1L downregulation in vivo.</p><p><strong>Results: </strong>CHD1L was highly expressed in OC tissues and OC cells. Interference with CHD1L significantly inhibited proliferation, promoted apoptosis, induced cycle arrest, suppressed migration and invasion as well as enhanced the sensitivity of CAOV-3 cells to cisplatin. Additionally, CHD1L could interact with PLK1. PLK1 upregulation restored the impacts of CHD1L knockdown on the proliferation, apoptosis, cycle arrest, migration, invasion and the sensitivity of OC cells to cisplatin. It could be also found that CHD1L knocked down limited the tumor volume, downregulated PLK1, Ki67 and cleaved caspse3 expression.</p><p><strong>Conclusion: </strong>Taken together, interference with CHD1L inhibited the malignant progression and enhanced cisplatin sensitivity of OC cells by binding PLK1.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"38"},"PeriodicalIF":3.8,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143492180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is it time to abandon staging surgery and prolonged follow-up in patients with primary adult-type granulosa cell tumor?","authors":"Geertruid J Brink, Jolijn W Groeneweg, Ariane A Sickinghe, Hans W Nijman, Luc R C W van Lonkhuijzen, Christianne A R Lok, Jurgen M J Piek, Eva Maria Roes, Cornelis D de Kroon, Ward Hofhuis, Geertruida N Jonges, Eelke H Gort, Petronella O Witteveen, Ronald P Zweemer","doi":"10.1186/s13048-025-01622-5","DOIUrl":"10.1186/s13048-025-01622-5","url":null,"abstract":"<p><strong>Background: </strong>As current literature does not provide sufficient data to support clear guidelines in patients with a rare adult-type granulosa cell tumor, we aim to investigate: (1) whether additional staging surgery following primary surgical treatment is necessary; (2) how long standard follow-up should be and (3) risk factors for disease recurrence.</p><p><strong>Methods: </strong>A national multicenter prospective study was initiated in April 2018. Patients with suspected or confirmed adult-type granulosa cell tumor were eligible. Data on staging, follow-up and risk factors were both retrospectively and prospectively collected from medical records, and patients were followed until April 2024 or until death. Descriptive statistical analysis and survival analysis were performed using Cox regression methods and Kaplan-Meier analyses.</p><p><strong>Results: </strong>In total, 208 patients with histopathologically confirmed adult-type granulosa cell tumor were included, with a median follow-up of 5.5 years (IQR: 2.2-12.3 years). Vaginal bleeding and abdominal pain were the most common symptoms at diagnosis. Median time until first recurrence was 4.2 years (range 2 months- 32 years). Additional staging surgery did not reduce the risk of recurrence. During follow-up, most patients had no symptoms at the time of detection of recurrence. No difference in overall survival was found between patients who were diagnosed with a recurrence during follow-up, and those who were no longer in follow-up and presented with symptoms.</p><p><strong>Conclusions: </strong>Staging surgery does not improve recurrence free survival in patients with adult-type granulosa cell tumor. Our results suggest that adult-type granulosa cell tumor patients can be discharged from follow-up of adult-type granulosa cell tumor after five years.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"37"},"PeriodicalIF":3.8,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}